Schneeweiss, A., Park-Simon, T., Albanell, J., Lassen, U., Cortes, J., Dieras, V., . . . Cervantes, A. (2018). Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Investigational new drugs, 36(5), . https://doi.org/10.1007/s10637-018-0562-4
Chicago-Zitierstil (17. Ausg.)Schneeweiss, Andreas, et al. "Phase Ib Study Evaluating Safety and Clinical Activity of the Anti-HER3 Antibody Lumretuzumab Combined with the Anti-HER2 Antibody Pertuzumab and Paclitaxel in HER3-positive, HER2-low Metastatic Breast Cancer." Investigational New Drugs 36, no. 5 (2018). https://doi.org/10.1007/s10637-018-0562-4.
MLA-Zitierstil (9. Ausg.)Schneeweiss, Andreas, et al. "Phase Ib Study Evaluating Safety and Clinical Activity of the Anti-HER3 Antibody Lumretuzumab Combined with the Anti-HER2 Antibody Pertuzumab and Paclitaxel in HER3-positive, HER2-low Metastatic Breast Cancer." Investigational New Drugs, vol. 36, no. 5, 2018, https://doi.org/10.1007/s10637-018-0562-4.